Zevra Therapeutics Stock

Zevra Therapeutics ROCE 2024

Zevra Therapeutics ROCE

-0.8

Ticker

ZVRA

ISIN

US4884452065

WKN

A2QLX7

In 2024, Zevra Therapeutics's return on capital employed (ROCE) was -0.8, a 176.85% increase from the -0.29 ROCE in the previous year.

Zevra Therapeutics Aktienanalyse

What does Zevra Therapeutics do?

KemPharm Inc. is a biopharmaceutical company founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm uses its own proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety than existing medications. The business model of KemPharm is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form in the body. KemPharm utilizes its proprietary technology platform to design specific chemical compounds that are converted into the active form by a biological enzyme naturally present in the body. The advantages of such prodrugs are improved bioavailability, longer duration of action, and reduced toxicity. KemPharm has several business divisions: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is the division where research and development of new drugs are conducted. KemPharm has several prodrugs in the development phase, including KP415, KP484, and KP879, each being developed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is the division where clinical trials and regulatory approval of new drugs are conducted. The company has conducted several phase II and phase III trials for its prodrugs and plans to obtain commercial approval for its first products in the coming years. KemPharm Licensing is the division where KemPharm licenses its technology platform to other companies. The company has already formed several partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships aim to enable the use of KemPharm's prodrugs in other products and increase revenue. Kempharm Manufacturing is the division where KemPharm's drugs are manufactured. KemPharm collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is the division where KemPharm sells its prodrugs directly to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution and specialized sales channels. Overall, KemPharm has a promising portfolio of prodrugs that have potential for many medical applications. The company has the potential to become a major player in the pharmaceutical industry. KemPharm Inc. is a biopharmaceutical company that was founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm utilizes its proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety compared to existing medications. KemPharm's business model is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form within the body. Using its proprietary technology platform, KemPharm designs specific chemical compounds that can be converted into their active forms by a naturally occurring biological enzyme within the body. The advantages of these prodrugs include improved bioavailability, longer duration of action, and reduced toxicity. KemPharm operates in several business areas: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is responsible for the research and development of new drugs. KemPharm currently has several prodrugs in the developmental stage, such as KP415, KP484, and KP879, each designed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is responsible for conducting clinical studies and obtaining regulatory approval for new drugs. The company has conducted multiple phase II and phase III studies for its prodrugs and plans to obtain commercial approval for its first products in the upcoming years. KemPharm Licensing is responsible for licensing KemPharm's technology platform to other companies. The company has already formed partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships enable the utilization of KemPharm's prodrugs in other products and contribute to revenue growth. Kempharm Manufacturing is responsible for the production of KemPharm's drugs. The company collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is responsible for the direct sales of KemPharm's prodrugs to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution channels and specialized distribution channels. Overall, KemPharm has a promising portfolio of prodrugs with potential applications in various medical fields. The company has the potential to become a significant player in the pharmaceutical industry. Zevra Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Zevra Therapeutics's Return on Capital Employed (ROCE)

Zevra Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Zevra Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Zevra Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Zevra Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Zevra Therapeutics stock

What is the ROCE (Return on Capital Employed) of Zevra Therapeutics this year?

The ROCE of Zevra Therapeutics is -0.8 undefined this year.

How has the ROCE (Return on Capital Employed) of Zevra Therapeutics developed compared to the previous year?

The ROCE of Zevra Therapeutics has increased by 176.85% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Zevra Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Zevra Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Zevra Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Zevra Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Zevra Therapeutics impact the company?

An increase in the ROCE of Zevra Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Zevra Therapeutics affect the company?

A decrease in ROCE of Zevra Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Zevra Therapeutics?

Some factors that can affect Zevra Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Zevra Therapeutics so important for investors?

The ROCE of Zevra Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Zevra Therapeutics take to improve the ROCE?

To improve the ROCE, Zevra Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Zevra Therapeutics pay?

Over the past 12 months, Zevra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zevra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Zevra Therapeutics?

The current dividend yield of Zevra Therapeutics is .

When does Zevra Therapeutics pay dividends?

Zevra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zevra Therapeutics?

Zevra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zevra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zevra Therapeutics located?

Zevra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zevra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zevra Therapeutics from 12/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did Zevra Therapeutics pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of Zevra Therapeutics in the year 2023?

In the year 2023, Zevra Therapeutics distributed 0 USD as dividends.

In which currency does Zevra Therapeutics pay out the dividend?

The dividends of Zevra Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zevra Therapeutics

Our stock analysis for Zevra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zevra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.